| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sara Rezzola | Q85516811 |
| Francesco Semeraro | Q56979062 | ||
| Roberto dell'Omo | Q42772639 | ||
| P2093 | author name string | M R Romano | |
| C Costagliola | |||
| A Cancarini | |||
| P2860 | cites work | High mobility group box protein-1 in experimental autoimmune uveoretinitis | Q83200155 |
| Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis | Q84283942 | ||
| Deleterious role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury | Q85096646 | ||
| Effect of intravitreal bevacizumab on serum, aqueous, and vitreous humor levels of erythropoietin in patients with proliferative diabetic retinopathy | Q85910681 | ||
| Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy | Q86918206 | ||
| Serum and intraocular concentrations of erythropoietin and vascular endothelial growth factor in patients with type 2 diabetes and proliferative retinopathy | Q87986111 | ||
| Interleukin 6 induces the expression of vascular endothelial growth factor | Q24316308 | ||
| An endotoxin-induced serum factor that causes necrosis of tumors | Q24564406 | ||
| Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo | Q24678892 | ||
| Microvascular complications and diabetic retinopathy: recent advances and future implications | Q26822476 | ||
| Targeting inflammation in diabetes: Newer therapeutic options | Q26852726 | ||
| Pathophysiology of diabetic retinopathy | Q26865897 | ||
| Vascular endothelial growth factor-B in physiology and disease | Q27003400 | ||
| Therapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathy | Q27021701 | ||
| Vitreous mediators in retinal hypoxic diseases | Q27028225 | ||
| Biochemistry and molecular cell biology of diabetic complications | Q28131781 | ||
| Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression | Q28192264 | ||
| Salicylate-based anti-inflammatory drugs inhibit the early lesion of diabetic retinopathy | Q28218437 | ||
| Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic | Q28235623 | ||
| High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal | Q28242907 | ||
| Hydroxylation of HIF-1: oxygen sensing at the molecular level | Q28276549 | ||
| Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos | Q28506172 | ||
| Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice | Q28508807 | ||
| Costimulation of fibroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specific receptors | Q28573949 | ||
| Intraocular expression and release of high-mobility group box 1 protein in retinal detachment | Q28574646 | ||
| Disruption of adiponectin causes insulin resistance and neointimal formation | Q28589597 | ||
| IL-1 is required for tumor invasiveness and angiogenesis | Q28594748 | ||
| Increased IL-6 levels are not related to NF-κB or HIF-1α transcription factors activity in the vitreous of proliferative diabetic retinopathy. | Q51542620 | ||
| Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. | Q51628940 | ||
| Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. | Q52539642 | ||
| Adiponectin may play a part in the pathogenesis of diabetic retinopathy. | Q53891441 | ||
| Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. | Q54578226 | ||
| Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. | Q54580507 | ||
| Interleukin-6 and the matrix metalloproteinase response in the vitreous during proliferative vitreoretinopathy | Q58217632 | ||
| Osteopontin (Eta-1) and Fibroblast Growth Factor-2 Cross-Talk in Angiogenesis | Q59418933 | ||
| Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications | Q59489258 | ||
| Aqueous humor levels of vascular endothelial growth factor and adiponectin in patients with type 2 diabetes before and after intravitreal bevacizumab injection | Q61041498 | ||
| Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy | Q62019449 | ||
| Cytokines in proliferative vitreoretinopathy | Q63407755 | ||
| Basic Fibroblast Growth Factor Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy | Q67660782 | ||
| Ocular inflammatory effects of intravitreal interleukin 1 | Q68828706 | ||
| Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells. | Q40370860 | ||
| Regulation of erythropoietin production. New insights into molecular mechanisms of oxygen homeostasis. | Q40590491 | ||
| Potential role of glial cell line-derived neurotrophic factor receptors in Müller glial cells during light-induced retinal degeneration | Q40620538 | ||
| SDF-1 is both necessary and sufficient to promote proliferative retinopathy. | Q40743408 | ||
| Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo | Q40962410 | ||
| Emerging multipotent aspects of hepatocyte growth factor | Q41066829 | ||
| Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro | Q41190176 | ||
| Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy | Q41391165 | ||
| Nuclear factor-kappa B. | Q41598098 | ||
| Angiogenic Factors and Cytokines in Diabetic Retinopathy | Q41883466 | ||
| Expression of hypoxia-inducible factor-1alpha and the protein products of its target genes in diabetic fibrovascular epiretinal membranes | Q41943468 | ||
| Hepatocyte growth factor in vitreous and serum from patients with proliferative diabetic retinopathy | Q41957264 | ||
| Immunohistochemical demonstration of cellular fibronectin and tenascin in human epiretinal membranes | Q41968954 | ||
| MHC class II antigen expression by ocular cells in proliferative diabetic retinopathy. | Q42505345 | ||
| Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells | Q42518718 | ||
| Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus | Q42698660 | ||
| Landmark advances in the development of erythropoietin | Q42787068 | ||
| Erythropoietin: when liability becomes asset in neurovascular repair | Q42972651 | ||
| Role of interleukin-1beta in the pathogenesis of diabetic retinopathy | Q43007582 | ||
| Is diabetic retinopathy an inflammatory disease? | Q43009558 | ||
| Expression of stromal cell-derived factor-1 in diabetic retinopathy. | Q43055511 | ||
| Diabetes-enhanced tumor necrosis factor-alpha production promotes apoptosis and the loss of retinal microvascular cells in type 1 and type 2 models of diabetic retinopathy | Q43160577 | ||
| Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. | Q43592482 | ||
| Intravitreal VEGF and bFGF produce florid retinal neovascularization and hemorrhage in the rabbit | Q43637135 | ||
| Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. | Q43820960 | ||
| Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. | Q43843382 | ||
| Oxidative state of glutathione in red blood cells and plasma of diabetic patients: in vivo and in vitro study | Q44176536 | ||
| Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases | Q44235661 | ||
| Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model | Q44264318 | ||
| The Role of Advanced Glycation End Products in Retinal Microvascular Leukostasis | Q44595283 | ||
| Induction of IL-8, MCP-1, and bFGF by TNF-alpha in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation | Q44804461 | ||
| A central role for inflammation in the pathogenesis of diabetic retinopathy | Q44961996 | ||
| Soluble vascular adhesion protein-1 accumulates in proliferative diabetic retinopathy | Q45053063 | ||
| Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. | Q45166067 | ||
| Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor I. | Q45253713 | ||
| Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis | Q46128262 | ||
| Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Müller cells. | Q46298904 | ||
| Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: Analysis of vitreous samples | Q46333684 | ||
| Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy | Q46417808 | ||
| Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease | Q46554065 | ||
| Erythropoietin attenuated high glucose-induced apoptosis in cultured human aortic endothelial cells | Q46579641 | ||
| Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. | Q46581925 | ||
| Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion | Q46656451 | ||
| Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy | Q46667958 | ||
| Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes | Q46817516 | ||
| Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis | Q46930334 | ||
| Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia | Q48072985 | ||
| VEGF increases retinal vascular ICAM-1 expression in vivo. | Q48171299 | ||
| Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy | Q48605197 | ||
| Mechanisms linking obesity to insulin resistance and type 2 diabetes | Q29614887 | ||
| 5-Lipoxygenase, but not 12/15-lipoxygenase, contributes to degeneration of retinal capillaries in a mouse model of diabetic retinopathy | Q30393975 | ||
| Increased expression of placenta growth factor in proliferative diabetic retinopathy. | Q32126116 | ||
| Erythropoietin and VEGF exhibit equal angiogenic potential | Q33184235 | ||
| Expression of erythropoietin and its receptor in the human retina: a comparative study of diabetic and nondiabetic subjects | Q33323266 | ||
| Diabetic macular edema: pathogenesis and treatment | Q33403121 | ||
| Vitreal levels of erythropoietin are increased in patients with retinal vein occlusion and correlate with vitreal VEGF and the extent of macular edema | Q33593437 | ||
| Diabetic macular edema: new concepts in patho-physiology and treatment | Q33713517 | ||
| Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox | Q33747359 | ||
| The role of cyclooxygenases in inflammation, cancer, and development | Q33814331 | ||
| Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy | Q33930304 | ||
| Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage | Q34082890 | ||
| Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades | Q34086191 | ||
| Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress | Q34154404 | ||
| Erythropoietin--an endogenous retinal survival factor | Q34164129 | ||
| TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability | Q34237700 | ||
| Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. | Q34280300 | ||
| Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders | Q34292807 | ||
| Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy | Q34324536 | ||
| Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy | Q34426246 | ||
| Tumor necrosis factor-α signaling in macrophages. | Q34734335 | ||
| Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? | Q34976913 | ||
| TNFalpha is required for late BRB breakdown in diabetic retinopathy, and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis | Q35005977 | ||
| Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy | Q35102944 | ||
| High-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathy | Q35108807 | ||
| Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses | Q35173629 | ||
| High glucose stimulates the expression of erythropoietin in rat glomerular epithelial cells | Q35285579 | ||
| Localisation of vascular endothelial growth factor and its receptors to cells of vascular and avascular epiretinal membranes | Q35298251 | ||
| Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management | Q35299525 | ||
| Macrophage migration inhibitory factor levels in the vitreous of patients with proliferative diabetic retinopathy | Q35314709 | ||
| Role of inflammation in diabetic macular edema | Q35363372 | ||
| Growth factors in proliferative diabetic retinopathy | Q35605154 | ||
| CXC chemokines: the regulatory link between inflammation and angiogenesis. | Q35708206 | ||
| Advanced glycation end-products and the progress of diabetic vascular complications. | Q35717287 | ||
| Receptor activator of nuclear factor-κB ligand (RANKL) protects against hepatic ischemia/reperfusion injury in mice | Q35748574 | ||
| Adiponectin: A novel adipokine linking adipocytes and vascular function | Q35794441 | ||
| Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. | Q35798412 | ||
| High-mobility group box 1 protein is implicated in advanced glycation end products-induced vascular endothelial growth factor A production in the rat retinal ganglion cell line RGC-5. | Q35891564 | ||
| The role of growth factors in the pathogenesis of diabetic retinopathy | Q35906962 | ||
| Demonstration of vasoproliferative activity from mammalian retina | Q36201178 | ||
| The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions | Q36232160 | ||
| VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. | Q36371399 | ||
| Erythropoietin deficiency decreases vascular stability in mice. | Q36404124 | ||
| Oxygen-dependent diseases in the retina: role of hypoxia-inducible factors | Q36496079 | ||
| Vascular endothelial growth factor and its relationship to inflammatory mediators | Q36823246 | ||
| Vascular endothelial growth factor in eye disease | Q36929380 | ||
| Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy | Q37065496 | ||
| FOXO1 plays an important role in enhanced microvascular cell apoptosis and microvascular cell loss in type 1 and type 2 diabetic rats | Q37141739 | ||
| Proliferative vitreoretinopathy after eye injuries: an overexpression of growth factors and cytokines leading to a retinal keloid | Q37250122 | ||
| TNF-alpha levels in tears: a novel biomarker to assess the degree of diabetic retinopathy | Q37292151 | ||
| Inflammatory cytokines in vascular dysfunction and vascular disease | Q37315106 | ||
| T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo | Q37354355 | ||
| Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications | Q37512877 | ||
| Regulation of inflammasome activity. | Q37750913 | ||
| Role of endothelial chemokines and their receptors during inflammation | Q37833076 | ||
| Microvascular modifications in diabetic retinopathy | Q37879581 | ||
| Inflammation in diabetic retinopathy | Q37884176 | ||
| Inflammation and diabetic retinal microvascular complications | Q37911285 | ||
| Roles of IL-8 in ocular inflammations: a review. | Q37959540 | ||
| Signaling in innate immunity and inflammation | Q37980557 | ||
| Diabetic retinopathy and atherosclerosis: is there a link? | Q38055207 | ||
| Pericyte loss in diabetic retinopathy: mechanisms and consequences. | Q38112706 | ||
| Glial cell expression of hepatocyte growth factor in vitreoretinal proliferative disease. | Q38340883 | ||
| Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus | Q39197051 | ||
| Hyperglycaemia-induced pro-inflammatory responses by retinal Müller glia are regulated by the receptor for advanced glycation end-products (RAGE). | Q39656639 | ||
| Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations | Q39697208 | ||
| Acute intensive insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1alpha and VEGF. | Q39737660 | ||
| Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes | Q40017265 | ||
| Functional characteristics of connective tissue growth factor on vitreoretinal cells | Q40170425 | ||
| Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. | Q40305741 | ||
| Erythropoietin | Q70139862 | ||
| Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group | Q70215909 | ||
| Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy | Q70962898 | ||
| Localization of vascular endothelial growth factor in human retina and choroid | Q71226459 | ||
| During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium | Q71472059 | ||
| Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells | Q71695560 | ||
| Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy | Q72070446 | ||
| Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia | Q72331358 | ||
| Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells | Q73258549 | ||
| Tumor necrosis factor-alpha (TNF-alpha)-induced optic neuropathy in rabbits | Q73365317 | ||
| Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR) | Q73544419 | ||
| Kinetics of placenta growth factor/vascular endothelial growth factor synergy in endothelial hydraulic conductivity and proliferation | Q73629689 | ||
| Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes | Q73640405 | ||
| Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study | Q73715941 | ||
| Mechanisms of hepatocyte growth factor-induced retinal endothelial cell migration and growth | Q73876364 | ||
| Comparison of serum NO, TNF-alpha, IL-1beta, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus | Q78040840 | ||
| Basement membrane and growth factor gene expression in normal and diabetic human retinas | Q78094389 | ||
| Tenascin-C levels in the vitreous of patients with proliferative diabetic retinopathy | Q78290590 | ||
| Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy | Q78579831 | ||
| Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy | Q79138206 | ||
| Inhibition of caspase-1/interleukin-1beta signaling prevents degeneration of retinal capillaries in diabetes and galactosemia | Q79456121 | ||
| Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy | Q79563519 | ||
| Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products | Q79655377 | ||
| Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes | Q79706914 | ||
| Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema | Q80175166 | ||
| Novel role of erythropoietin in proliferative diabetic retinopathy | Q80270453 | ||
| Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients | Q80350462 | ||
| Monocyte chemoattractant protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A | Q80894668 | ||
| Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy | Q81118852 | ||
| Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy | Q81142796 | ||
| Increased levels of monokine induced by interferon-gamma (Mig) in the vitreous of patients with diabetic retinopathy | Q81678437 | ||
| Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy | Q81775373 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | inflammation | Q101991 |
| hypoxia | Q105688 | ||
| cytokine | Q212354 | ||
| diabetic retinopathy | Q631361 | ||
| oxidative stress | Q898814 | ||
| retinal vessels | Q70305596 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 582060 | |
| P577 | publication date | 2015-06-07 | |
| P1433 | published in | Journal of Diabetes Research | Q26841822 |
| P1476 | title | Diabetic Retinopathy: Vascular and Inflammatory Disease | |
| P478 | volume | 2015 |
| Q50861252 | 1,25-Dihydroxyvitamin D3 Deficiency is Involved in the Pathogenesis of Diabetic Retinopathy in the Uygur Population of China. |
| Q48349526 | 3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. |
| Q41468154 | A Critical Analysis of the Available In Vitro and Ex Vivo Methods to Study Retinal Angiogenesis. |
| Q33588022 | A novel immunodeficient NOD.SCID-rd1 mouse model of retinitis pigmentosa to investigate potential therapeutics and pathogenesis of retinal degeneration |
| Q92599989 | A review of the putative causal mechanisms associated with lower macular pigment in diabetes mellitus |
| Q53111788 | Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy. |
| Q38941639 | Application of multiplex immunoassay technology to investigations of ocular disease |
| Q64093346 | Biological Characteristics of Subsilicone Oil Fluid and Differences With Other Ocular Humors |
| Q33583030 | Biomarkers in Diabetic Retinopathy |
| Q38715502 | Blocking IL-17A Alleviates Diabetic Retinopathy in Rodents |
| Q26749552 | Bone Marrow-Derived Stem Cells: a Mixed Blessing in the Multifaceted World of Diabetic Complications |
| Q28073127 | Candidate gene studies of diabetic retinopathy in human |
| Q41572871 | Cellular Reparative Mechanisms of Mesenchymal Stem Cells for Retinal Diseases |
| Q91669767 | Characterising an Alternative Murine Model of Diabetic Cardiomyopathy |
| Q47870702 | Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. |
| Q92461198 | Convolutional Neural Networks for Spectroscopic Analysis in Retinal Oximetry |
| Q92358483 | Corneal Neuropathy: An Underrated Manifestation of Diabetes Mellitus |
| Q42699559 | Diabetic Retinopathy and Laser Therapy in Rats: A Protein-Protein Interaction Network Analysis |
| Q26765466 | Diabetic Retinopathy: Animal Models, Therapies, and Perspectives |
| Q37535413 | Dietary Compound Chrysin Inhibits Retinal Neovascularization with Abnormal Capillaries in db/db Mice |
| Q64117714 | Downregulation of lncRNA BANCR participates in the development of retinopathy among diabetic patients |
| Q37026774 | Effect of periocular injection of celecoxib and propranolol on ocular level of vascular endothelial growth factor in a diabetic mouse model |
| Q90518624 | Effects of retinopathy and chronic kidney disease on long-term mortality in type 2 diabetic inpatients with normal urinary albumin or protein: a retrospective cohort study |
| Q38648612 | Fluocinolone acetonide for the treatment of diabetic macular edema |
| Q90414841 | Glucose-Regulated Protein 78 in the Aqueous Humor of Patients with Diabetic Macular Edema |
| Q46087453 | Glycated albumin (GA) and inflammation: role of GA as a potential marker of inflammation. |
| Q38699768 | Hypoxia and inflammation in the release of VEGF and interleukins from human retinal pigment epithelial cells |
| Q37538552 | IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling |
| Q51791449 | ILM peeling in nontractional diabetic macular edema: review and metanalysis. |
| Q90056307 | In vivo imaging of corneal nerves and cellular structures in mice with Gabor-domain optical coherence microscopy |
| Q64102943 | Increased plasma galectin-1 correlates with advanced glycation end products and interleukin-1β in patients with proliferative diabetic retinopathy |
| Q46433119 | Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. |
| Q98288337 | Inflammatory and angiogenic biomarkers in diabetic retinopathy |
| Q33634491 | Inpatient screening for albuminuria and retinopathy to predict long-term mortality in type 2 diabetic patients: a retrospective cohort study |
| Q58597196 | Intraocular Hemorrhage due to use of Sildenafil in a Patient with Diabetes |
| Q91362432 | Intravitreal injection of adenosine A2A receptor antagonist reduces neuroinflammation, vascular leakage and cell death in the retina of diabetic mice |
| Q41925161 | Investigation of the Effects and Mechanisms of Mai Tong Formula on Lower Limb Macroangiopathy in a Spontaneous Diabetic Rat Model |
| Q90096832 | Investigation of the therapeutic mechanism of subthreshold micropulse laser irradiation in retina |
| Q64911014 | Is There A Role for Abscisic Acid, A Proven Anti-Inflammatory Agent, in the Treatment of Ischemic Retinopathies? |
| Q48095108 | Ischemic Retinopathies: Oxidative Stress and Inflammation. |
| Q55003873 | Levels of Inflammatory Cytokines IL-1β, IL-6, IL-8, IL-17A, and TNF-α in Aqueous Humour of Patients with Diabetic Retinopathy. |
| Q61453542 | Long Non-Coding RNA of Myocardial Infarction Associated Transcript (LncRNA-MIAT) Promotes Diabetic Retinopathy by Upregulating Transforming Growth Factor-β1 (TGF-β1) Signaling |
| Q57750182 | Loss of Angiotensin-Converting Enzyme 2 Exacerbates Diabetic Retinopathy by Promoting Bone Marrow Dysfunction |
| Q60956883 | Lymphatic Vascular Structures: A New Aspect in Proliferative Diabetic Retinopathy |
| Q91762118 | MicroRNAs as biomarkers of diabetic retinopathy and disease progression |
| Q28078199 | Moving Past Anti-VEGF: Novel Therapies for Treating Diabetic Retinopathy |
| Q49911705 | O-Linked β-N-acetylglucosamine (O-GlcNAc) modification: a new pathway to decode pathogenesis of diabetic retinopathy |
| Q36290885 | Obesity and diabetic retinopathy: What is the association? |
| Q26749412 | Ocular Complications of Diabetes and Therapeutic Approaches |
| Q53104045 | Ocular Surface Characteristics in Diabetic Children. |
| Q90070032 | Oxidative Stress as the Main Target in Diabetic Retinopathy Pathophysiology |
| Q26776171 | Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy |
| Q36318318 | Peripheral blood metabolic and inflammatory factors as biomarkers to ocular findings in diabetic macular edema |
| Q92254403 | Physical Activity, Muscle-Strengthening Activities, and Systemic Inflammation Among Retinopathy Patients |
| Q93184878 | Poly(lactic-co-glycolic acid) nanoparticle-mediated interleukin-12 delivery for the treatment of diabetic retinopathy |
| Q89173610 | Poorer Visual Acuity Is Associated with Declines in Cognitive Performance Across Multiple Cognitive Domains: The Maine-Syracuse Longitudinal Study |
| Q52609620 | Potential Interplay between Hyperosmolarity and Inflammation on Retinal Pigmented Epithelium in Pathogenesis of Diabetic Retinopathy. |
| Q92909144 | Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with diabetic macular edema treated with ranibizumab |
| Q93181086 | Protection by vitamin D against high-glucose-induced damage in retinal pigment epithelial cells |
| Q99561828 | Retinal Physiology and Circulation: Effect of Diabetes |
| Q47097264 | Rhein lysinate protects renal function in diabetic nephropathy of KK/HlJ mice |
| Q26775853 | Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant |
| Q64054738 | Role of ω3 polyunsaturated fatty acids in diabetic retinopathy: a morphological and metabolically cross talk among blood retina barriers damage, autoimmunity and chronic inflammation |
| Q33845071 | Roles of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase in Angiogenesis: Isoform-Specific Effects |
| Q33914624 | Scutellaria barbata attenuates diabetic retinopathy by preventing retinal inflammation and the decreased expression of tight junction protein |
| Q39761684 | The Eye is the Window to the Kidney and Brain. |
| Q64257354 | The Preventive Effect of Oxytocin on Retinopathy in Streptozotocin-Induced Diabetic Rats |
| Q48308877 | The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. |
| Q55512530 | The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. |
| Q38762998 | The role of dyslipidemia in diabetic retinopathy |
| Q42373000 | Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy |
| Q91893478 | Up-regulation of pro-angiogenic pathways and induction of neovascularization by an acute retinal light damage |
| Q51266257 | Zerumbone, a Bioactive Sesquiterpene, Ameliorates Diabetes-Induced Retinal Microvascular Damage through Inhibition of Phospho-p38 Mitogen-Activated Protein Kinase and Nuclear Factor-κB Pathways. |
| Q37202605 | Zerumbone, a Phytochemical of Subtropical Ginger, Protects against Hyperglycemia-Induced Retinal Damage in Experimental Diabetic Rats |
| Q37487988 | miR-15a/16 reduces retinal leukostasis through decreased pro-inflammatory signaling |
Search more.